STUDIES
20 patients completed the KD-IF and 22 patients the SD as specified by the protocol from 50 recruited patients; Sample size was calculated to detect an increase of PFS6 from 0% (28) to 30% with a power of 80%, necessitating the recruitment of 50 patients in this trial with an anticipated drop-out rate of 8 patients. Inclusion criteria were: recurrence of a histologically confirmed glioblastoma, gliosarcoma or malignant progression of a lower grade glioma on MRI; age above 18 years; Karnofsky performance score (KPS) ≥60%; prior radiation therapy of the tumor at least 6 months before inclusion; prior therapy with temozolomide; multidisciplinary tumor board recommendation for re-irradiation; adequate hematologic, hepatic, renal and coagulatory function